Apricus Biosciences, Inc (NASDAQ:APRI)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research note issued on Wednesday. They presently have a $5.00 target price on the stock. HC Wainwright’s target price indicates a potential upside of 206.75% from the company’s previous close.

Separately, Zacks Investment Research downgraded shares of Apricus Biosciences from a “hold” rating to a “sell” rating in a research note on Tuesday, June 27th.

Apricus Biosciences (APRI) opened at 1.63 on Wednesday. The firm has a market cap of $20.84 million, a price-to-earnings ratio of 2.72 and a beta of 0.57. The firm has a 50-day moving average of $1.33 and a 200 day moving average of $1.58. Apricus Biosciences has a 52-week low of $0.86 and a 52-week high of $4.94.

Apricus Biosciences (NASDAQ:APRI) last posted its quarterly earnings results on Wednesday, August 2nd. The company reported ($0.15) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.16) by $0.01. On average, equities research analysts forecast that Apricus Biosciences will post ($0.81) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This article was posted by Watch List News and is the property of of Watch List News. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://www.watchlistnews.com/hc-wainwright-reiterates-5-00-price-target-for-apricus-biosciences-inc-apri/1531340.html.

Apricus Biosciences Company Profile

Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.

Receive News & Ratings for Apricus Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.